The clinical value of this class is compromised by the toxic side effects, however, which include methemoglobinaemia and haemolytic anaemia in patients with deficiency in glucose-6-phosphate dehydrogenase (G6PD) activity [2]. The gene discussed is G6PD; the disease is non-autoimmune hemolytic anemia.